<DOC>
	<DOC>NCT00463151</DOC>
	<brief_summary>The purpose of this study is to examine the safety and efficacy of rebamipide by once daily intracolonial administration at 0 (placebo), 60, 150, or 300 mg for 6 weeks in patients with active ulcerative colitis, who are being treated with oral aminosalicylic acid (ASA).</brief_summary>
	<brief_title>An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Rebamipide</mesh_term>
	<criteria>1. Patients with active ulcerative colitis 2. Patients having an insufficient response to ASA oral formulation: (1) Patients whose ongoing use of ASA oral formulation from ≥2 weeks prior to the day before registration is fixed at mesalazine ≥2 g/day or salazosulfapyridine 36 g/day, (2) Patients with continuous bloody stools from ≥2 weeks prior to the day before registration, (3) Patients whose DAI subscores are ≥2 points for "bloody stools" and ≥2 points for "endoscopic findings" 3. Patients shown via colonoscopy to have major lesions between the sigmoid colon and rectum (with lesions not extending beyond the splenic flexure) 4. Outpatients 1. Patients who have a history of intestinal resection (other than appendiceal resection) 2. Patients who have a complication of malignant tumor 3. Female patients who are pregnant, lactating, or possibly pregnant, or who hope to become pregnant during the study period 4. Patients who have complications of serious cardiac, hepatic or renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Rebamipide</keyword>
	<keyword>Enema</keyword>
	<keyword>Ulcerative Colitis</keyword>
</DOC>